CellaVision AB completes the acquisition of exclusive rights to novel microscopy technology
CellaVision has completed the previously announced acquisition of the exclusive rights to a patent portfolio on Fourier Ptychographic Microscopy, a novel microscopy technology from Clearbridge BioPhotonics.
The acquisition gives CellaVision access and control of an interesting future technology. The Fourier Ptychography Microscopy technology has potential to be used to develop future automated microscopes, with applications in both hematology and adjacent areas. The closing took place today and will have no impact on CellaVisions earnings per share during the current financial year.
Questions on the acquisition can be addressed to:
Simon Østergaard, President and CEO, CellaVision AB,
Direct: +46 (0) 700-36 37 92